Disclosures: Ahmed Elhariri: Nothing to Disclose, Manal Hassan: Nothing to Disclose, Mazen ELsheikh: Nothing to Disclose, Ahmed El sabagh: Nothing to Disclose, Mohamad Ali Ibrahim: Nothing to Disclose, Megha Bhongade: Nothing to Disclose, sali albarouki: Nothing to Disclose, Anish Nayak: Nothing to Disclose, Youseph Karouni: Nothing to Disclose, Prasun Jalal: Nothing to Disclose 1132 REAL-WORLD OUTCOMES OF PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) COMPENSATED CIRRHOSIS AT A LARGE ACADEMIC REFERRAL CENTER Shadera Slatter 1 Jordan Guillot 1 Christopher Williams 1 Alexandre Watanabe 2 Eirum Chaudhri 2 Xiao Zhang 2 Gail Fernandes 2 Jin Ge 3 Vivek Rudrapatna 1 , 1 Bakar Computational Health Sciences Institute, University of California, San Francisco, 2 Merck & Co., Inc., Rahway, NJ, USA, 3 University of California, San Francisco Background: Epidemiologic data on MASH compensated cirrhosis patients and their disease progression are limited
Frequently asked questions Do I have to snack at all on a GLP-1
Retrieved from Baxter, S
To explore these questions, the WashU Medicine team analyzed health data from more than 600,000 U.S
Q: Should I eat when I'm nauseous on GLP-1
